Drug intelligence / Profile preview

carboxymethylcellulose + vitamin D

Development stage: Unknown
Modality: Small Molecules
Administration: Ophthalmic, Buccal

Overview

A combination of carboxymethylcellulose (CMC) and vitamin D used for the treatment of dry eye disease, particularly in patients with vitamin D deficiency. Clinical studies have shown that this combination leads to earlier and significant improvement in tear breakup time (TBUT), Schirmer's test values, and ocular surface disease index (OSDI) scores compared to carboxymethylcellulose alone.

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on carboxymethylcellulose + vitamin D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboxymethylcellulose + vitamin D.

Explore the full profile